BSEM News and Press, BioStem Technologies Inc

POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today announced that Company management wi...

POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent re...

2026-01-22 10:14:44 ET BioStem Technologies, Inc. (BSEM) M&A Call January 22, 2026 8:00 AM EST Company Participants Philip Taylor - Associate Jason Matuszewski - CEO, President, Secretary & Chairman Barry Hassett - Chief Commercial Officer Brandon Poe...

Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem’s position across hospital settings Barry Hassett promoted to Chief Commercial Officer Confer...

Decision ensures continued patient access to VENDAJE ® and VENDAJE AC ® POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived pr...

Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains unaffected by CMS LCD updates    POMPAN...

POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced the launch of a new product line, American Amnion, at the Desert Foot Multi-Disciplinary Li...

POMPANO BEACH, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced expanded reimbursement with the inclusion of VENDAJE ® and VENDAJE AC ® i...

2025-11-13 19:51:35 ET BioStem Technologies, Inc. (BSEM) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST... Read the full article on Seeking Alpha For further details see: BioStem Technologies, Inc. (BSEM) Q3 2025 Earnings Call Transcript

2025-11-13 16:17:55 ET More on BioStem Technologies BioStem Technologies, Inc. (BSEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) Seeking Alpha’s Quant Rating on BioStem Technologies Historical earnings data for BioStem Tec...